CPHI
AMEXChina Pharma Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.16-0.04 (-3.33%)
04:15 PM06:45 PM
News · 26 weeks12+100%
2026-02-082026-08-02
Mix890d
- Other3(38%)
- SEC Filings3(38%)
- Offering2(25%)
Latest news
25 items- PRChina Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct OfferingHAIKOU, China, July 23, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) (the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced the closing of its previously announced registered direct offering of 2,500,000 shares of the Company's common stock, par value $0.001 per share, at a purchase price of $2.00 per share. The gross proceeds from the offering are $5 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The offering closed on July 23, 2026.FT Global Capital, Inc. is acting as the exclusive placement
- SECSEC Form 424B5 filed by China Pharma Holdings Inc.424B5 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Announces Pricing of $5 Million Registered Direct OfferingHAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that the pricing of its registered direct offering of 2.5 million shares of its common stock ("Common Shares"), at a purchase price of $2 per share. The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.The offering is expected to be closed on or about July 23, 2026. FT Global Capital, Inc. is acting as the exclusive
- PRChina Pharma Holdings, Inc. Comments on Unusual Market ActivityHAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it issued this statement under Section 401(d) of the NYSE American Company Guide that it was not aware of any material corporate developments that would explain the recent market activity. Shareholders and prospective inv
- PRChina Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market ActivityHAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity. About China Pharma Holdings, Inc. China
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market ActivityHAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 12 and 13, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity. About China Pharma Holdings, Inc. China Pharma Holdin
- SECSEC Form 10-K filed by China Pharma Holdings Inc.10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form NT 10-K filed by China Pharma Holdings Inc.NT 10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form DEF 14A filed by China Pharma Holdings Inc.DEF 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form PRE 14A filed by China Pharma Holdings Inc.PRE 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock SplitHAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401. The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by
- SECSEC Form 10-K filed by China Pharma Holdings Inc.10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
CPHI FAQ
5 questionsWhat does China Pharma Holdings Inc. do?
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to...Where does CPHI stock trade?
China Pharma Holdings Inc. (CPHI) is listed on AMEX.What sector and industry is CPHI in?
China Pharma Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to CPHI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CPHI side-by-side with any of them on Quantisnow.How can I track CPHI on Quantisnow?
Quantisnow aggregates China Pharma Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CPHI to receive live email and push alerts on every new disclosure.